Common Fund Programs
The NIH Common Fund is a funding entity within the NIH that supports bold scientific programs that catalyze discovery across all biomedical and behavioral research. These programs create a space where investigators and multiple NIH Institutes and Centers collaborate on innovative research expected to address high priority challenges for the NIH as a whole and make a broader impact in the scientific community. For more information on specific Common Fund Current Programs, Archived Initiatives, or Common Fund-supported COVID-19 Research, click on each tab below.
- 4D Nucleome (4DN)
- Acute to Chronic Pain Signatures (A2CPS)
- Bridge to Artificial Intelligence (Bridge2AI)
- Cellular Senescence Network (SenNet)
- Common Fund Data Ecosystem (CFDE)
- Community Partnerships to Advance Science for Society (ComPASS)
- Diversity Program Consortium (DPC):
Enhancing the Diversity of the NIH-Funded Workforce
- Extracellular RNA Communication (ExRNA)
- Faculty Institutional Recruitment for
Sustainable Transformation (FIRST)
- Gabriella Miller Kids First (Kids First)
- Global Health
- Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa)
- High-Risk, High-Reward Research (HRHR)
- The Human BioMolecular Atlas Program (HuBMAP)
- Human Virome Program
- Illuminating the Druggable Genome (IDG)
- Molecular Transducers of Physical Activity in Humans (MoTrPAC)
- Nutrition for Precision Health, powered by the All of Us Research Program
- Somatic Cell Genome Editing (SCGE)
- Somatic Mosaicism Across Human Tissues (SMaHT)
- Stimulating Peripheral Activity to Relieve Conditions (SPARC)
- Transformative High Resolution Cryo-Electron Microscopy (CryoEM)
- Transformative Research to Address
Health Disparities and Advance Health Equity
General Categories of Common Fund Programs
The goals of Common Fund programs align with three general categories:
- Advancing Health Communication Science and Practice
- Big Data to Knowledge (BD2K)
- Bioinformatics and Computational Biology
- Bridging Interventional Development Gaps (BrIDGs)
- Building Blocks, Biological Pathways and Networks (BBPN)
- Clinical and Translational Science Awards (CTSAs)
- Clinical Research Policy Analysis and Coordination (CRPac)
- Genotype-Tissue Expression (GTEx)
- Gulf Oil Spill
- Healthcare Systems Research (HCS) Collaboratory
- Health Economics
- Human Microbiome Project
- Knockout Mouse Phenotyping Program (KOMP2)
- Interdisciplinary Research
- Library of Integrated Network-based Cellular Signatures (LINCS)
- Molecular Libraries and Imaging
- National Electronics Clinical Trials and Research (NECTAR)
- New Models of Data Stewardship
- NIH Medical Research Scholars Program
- Patient-Reported Outcomes Measurement Information System (PROMIS)
- Protein Capture Reagents Program (PCRP)
- Regenerative Medicine Program
- Regulatory Science
- Science of Behavior Change
- Single Cell Analysis
- Strengthening the Biomedical Research Workforce
- Structural Biology
- Undiagnosed Diseases Network (UDN)
Common Fund programs capitalize on emerging opportunities to catalyze the rate of progress across multiple biomedical fields. Programs are expected to transform the way a broad spectrum of health research is conducted. Initiatives that comprise Common Fund programs are intended to be catalytic in nature by providing limited term investments in strategic areas to stimulate further research through IC-funded mechanisms.
For these reasons, programs are intended to transition out of the Common Fund in 10 years or less as they mature.
For more information on specific former Common Fund programs, please refer to the programs listed above.
Through the American Recovery and Reinvestment Act (ARRA), the Common Fund received approximately $137M to be spent in fiscal years 2009 and 2010. As a result several awards were funded across a range of biomedical research areas.
Support for COVID-19 Research
The NIH Common Fund received $30 Million from the Coronavirus Aid, Relief, and Economic Security (CARES) Act, 2020 to prevent, prepare for, and respond to coronavirus, domestically or internationally. The Office of Strategic Coordination (OSC), which manages the Common Fund is using these funds to stimulate innovative research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the disease it causes, Coronavirus Disease 2019 (COVID-19). OSC issued immediate funding opportunities in Fiscal Year 2020 for active Common Fund researchers to conduct SARS-CoV-2 and COVID-19 research. Awards issued through these funding opportunities are listed below.
Future Research Funding Opportunities
In future years, OSC will use CARES Act funds allocated to the NIH Common Fund for researchers to develop new research projects starting in Fiscal Year 2021. Continue to check this page for updates on future SARS-CoV-2 and COVID-19 research funding opportunities from the NIH Common Fund.
For a list of funding opportunities from multiple NIH Institutes, Centers, and Offices — including the NIH Common Fund — please visit the COVID-19 page of information for NIH applicants and recipients of NIH funding.
Emergency Competitive Revisions for Research on SARS-COV-2 and COVID-19
In Fiscal Year 2020, the Office of Strategic Coordination (OSC), issued a Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-RM-20-015) to stimulate innovative research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the disease it causes, Coronavirus Disease 2019 (COVID-19).
OSC issued emergency competitive revisions to Common Fund grants and cooperative agreements to support innovative research on COVID-19 or SARS-CoV-2 in areas of research including behavioral/social science, health disparities, and novel therapeutics, that fits within the mission of an emergency response to provide critical expertise, resources or activities. A list of funded projects is available on the Common Fund Support for COVID-19 funded research section below.
Due to the public health emergency, the Transformative Research Award and Early Independence Award issued additional funding opportunities for COVID-19-related research on the prevention of, preparation for, or response to coronavirus SARS-CoV-2 using funds provided through the CARES Act.
|PI Name||Institution Name||Title|
|DEB, ARJUN (contact); ARUMUGASWAMI, VAITHILINGARAJA ; GRAEBER, THOMAS G; PELLEGRINI, MATTEO||UNIVERSITY OF CALIFORNIA LOS ANGELES||Metabolic and Epigenetic Reprogramming of Vital Organs in SARS-CoV-2 Induced Systemic Toxicity|
|MANCEBO, RICARDO||GENENDEAVOR, LLC||Development of a Handheld Rapid Air Sensing System to Monitor and Quantify SARS-CoV-2 in Aerosols in Real-Time|
|RAY, ANIMESH (contact); HERNANDEZ, JENIFFER BERTHA||KECK GRADUATE INST OF APPLIED LIFE SCIS||Rapid Response for Pandemics: Single Cell Sequencing and Deep Learning to Predict Antibody Sequences Against an Emerging Antigen|
|WEINBERGER, LEOR S (contact); RODICK, ROBERT||VXBIOSCIENCES, INC.||Autonomously Deploying, Co-Evolving SARS-CoV-2 Antiviral: A New Paradigm for Pandemic Prevention|
|YAKOUB, ABRAAM M (contact); LAZARTIGUES, ERIC D; TSENG, CHIEN-TE K||UNIVERSITY OF NORTH DAKOTA||SARS-CoV-2 Tropism in the Brain and Its Relationship to COVID-19 Pathogenesis|